Skip to content

Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device

Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00361608
Enrollment
0
Registered
2006-08-08
Start date
2008-07-31
Completion date
2009-05-31
Last updated
2016-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type I Diabetes

Keywords

diabetes, hypoglycemia, monitor, children with Type I Diabetes

Brief summary

This study observes the continuous measurement of breathing patterns, heart rate, restlessness, and tremor in sleep using the EarlySense ES 16 device as a tool in the management of hypoglycemia in pediatric type I diabetes patients.

Detailed description

The study patients are children, 12-18 years old, suffering from type I diabetes. Each patient will participate in the trial for 30 days. During this period of time the patients' breathing patterns, heart rate, restlessness and tremor in sleep will be measured by the EarlySense device which is put in the patient's bed. These measured values will be compared to: 1. glucose values measured by a Guardian RT device - an approved device for CBGM - Continuous Blood Glucose Measurement; 2. glucose levels tested by SBGM -Self Blood Glucose Measurement. These comparisons will show whether the EarlySense device is applicable in predicting hypoglycemia events in type I diabetes patients.

Interventions

DEVICEEarlySense ES 16

Sponsors

Schneider Children's Medical Center, Israel
CollaboratorOTHER
EarlySense Ltd.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Age between 12-18 years * Diagnosis of type I diabetes for at least a year * Home close to participating center * Guardian able and willing to cooperate with the trial for at least 1 month and prepared to sign the Informed Consent Form.

Exclusion criteria

* Recent (within 3 months) admission to emergency room or intensive care unit (ICU) due to any condition unrelated directly to diabetes. * Any other pre-existing medical pathology unrelated to diabetes. * Inability of the patient or his guardian to use the Guardian RT.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026